Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia: San Diego Wednesday, November 13, 2024, 15:30 Hrs [IST] Aethl ...

Finally, the assay can be used with Merck’s Keytruda (pembrolizumab) and GSK’s Jemperli (dostarlimab) across solid tumors ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

LOUISVILLE, Ky. -- Large tumor size and high disease grade were associated with an increased risk of early cancer-related ...

"By 2024, the market is projected to reach a staggering US$597.00bn worldwide. Among these markets, Medical Devices are expected to dominate, with a projected market volume of US$508.00bn by 2024.

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® ...

“[In the trial], we used 12 weeks of weekly paclitaxel and carboplatin ... multicenter LEAP-012 trial (NCT04246177), lenvatinib (Lenvima) with pembrolizumab (Keytruda) and transarterial ...